Science 28 May 1993: Vol. 260. no. 5112, pp. 1317 - 1320 DOI: 10.1126/science.8493574

Prev | Table of Contents | Next

Articles

Von Hippel-Lindau Gene Product Modulates TIS11B Expression in Renal Cell Carcinoma: IMPACT ON VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN HYPOXIA.

S. Sinha, S. Dutta, K. Datta, A. K. Ghosh, and D. Mukhopadhyay (2009)
J. Biol. Chem. 284, 32610-32618
 |  Abstract »  |  Full Text »  |  PDF »

Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas.

P. Gergics, A. Patocs, M. Toth, P. Igaz, N. Szucs, I. Liko, F. Fazakas, I. Szabo, B. Kovacs, E. Glaz, et al. (2009)
Eur. J. Endocrinol. 161, 495-502
 |  Abstract »  |  Full Text »  |  PDF »

A novel germline mutation of the VHL gene in a Greek family with Von Hippel-Lindau disease.

M. Peppa, S. Kamakari, E. Boutati, P. Nikolopoulos, C. Giatzakis, T. Economopoulos, D. Hadjidakis, and S. A Raptis (2009)
BMJ Case Reports 2009, bcr0220091574
 |  Abstract »  |  Full Text »

Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management.

W. M. Linehan (2009)
J. Clin. Oncol. 27, 3731-3733
 |  Full Text »  |  PDF »

Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient.

B. I. Rini (2009)
J. Clin. Oncol. 27, 3225-3234
 |  Abstract »  |  Full Text »  |  PDF »

Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.

U. Srirangalingam, B. Khoo, L. Walker, F. MacDonald, R. H Skelly, E. George, D. Spooner, L. B Johnston, J. P Monson, A. B Grossman, et al. (2009)
Endocr. Relat. Cancer 16, 515-525
 |  Abstract »  |  Full Text »  |  PDF »

Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2.

C. C. Boedeker, Z. Erlic, S. Richard, U. Kontny, A.-P. Gimenez-Roqueplo, A. Cascon, M. Robledo, J. M. de Campos, F. H. van Nederveen, R. R. de Krijger, et al. (2009)
J. Clin. Endocrinol. Metab. 94, 1938-1944
 |  Abstract »  |  Full Text »  |  PDF »

Preimplantation genetic diagnosis using fluorescent in situ hybridization for cancer predisposition syndromes caused by microdeletions.

E. Vanneste, C. Melotte, S. Debrock, T. D'Hooghe, H. Brems, J.P. Fryns, E. Legius, and J.R. Vermeesch (2009)
Hum. Reprod. 24, 1522-1528
 |  Abstract »  |  Full Text »  |  PDF »

Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney.

R. Beroukhim, J.-P. Brunet, A. Di Napoli, K. D. Mertz, A. Seeley, M. M. Pires, D. Linhart, R. A. Worrell, H. Moch, M. A. Rubin, et al. (2009)
Cancer Res. 69, 4674-4681
 |  Abstract »  |  Full Text »  |  PDF »

Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up.

K. Oberg, S. Jelic, and On behalf of the ESMO Guidelines Working Group (2009)
Ann. Onc. 20, iv150-iv153
 |  Full Text »  |  PDF »

Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis.

J. Clague, J. Lin, A. Cassidy, S. Matin, N. M. Tannir, P. Tamboli, C. G. Wood, and X. Wu (2009)
Cancer Epidemiol. Biomarkers Prev. 18, 801-807
 |  Abstract »  |  Full Text »  |  PDF »

Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma.

T. Klatte, P. N. Rao, M. de Martino, J. LaRochelle, B. Shuch, N. Zomorodian, J. Said, F. F. Kabbinavar, A. S. Belldegrun, and A. J. Pantuck (2009)
J. Clin. Oncol. 27, 746-753
 |  Abstract »  |  Full Text »  |  PDF »

Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations.

I. Agalliu, R. Gern, S. Leanza, and R. D. Burk (2009)
Clin. Cancer Res. 15, 1112-1120
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of Renal Epithelial Tight Junctions by the von Hippel-Lindau Tumor Suppressor Gene Involves Occludin and Claudin 1 and Is Independent of E-Cadherin.

S. K. Harten, D. Shukla, R. Barod, A. Hergovich, M. S. Balda, K. Matter, M. A. Esteban, and P. H. Maxwell (2009)
Mol. Biol. Cell 20, 1089-1101
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Pathways and Targeted Therapies for Renal Cell Carcinoma.

J. Brugarolas (2009)
ASCO Educational Book 2009, 710-715
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.

K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi (2008)
Ann. Onc. 19, 1774-1786
 |  Abstract »  |  Full Text »  |  PDF »

Neurologic Manifestations of von Hippel-Lindau Disease.

J. A. Butman, W. M. Linehan, and R. R. Lonser (2008)
JAMA 300, 1334-1342
 |  Abstract »  |  Full Text »  |  PDF »

Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN.

E. R. Woodward, C. Ricketts, P. Killick, S. Gad, M.R. Morris, F. Kavalier, S. V. Hodgson, S. Giraud, B. Bressac-de Paillerets, C. Chapman, et al. (2008)
Clin. Cancer Res. 14, 5925-5930
 |  Abstract »  |  Full Text »  |  PDF »

Germline SDHB Mutations and Familial Renal Cell Carcinoma.

C. Ricketts, E. R. Woodward, P. Killick, M. R. Morris, D. Astuti, F. Latif, and E. R. Maher (2008)
J Natl Cancer Inst 100, 1260-1262
 |  Abstract »  |  Full Text »  |  PDF »

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors.

M. L. Nickerson, E. Jaeger, Y. Shi, J. A. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, et al. (2008)
Clin. Cancer Res. 14, 4726-4734
 |  Abstract »  |  Full Text »  |  PDF »

Endothelial Function of von Hippel-Lindau Tumor Suppressor Gene: Control of Fibroblast Growth Factor Receptor Signaling.

K. J. Champion, M. Guinea, V. Dammai, and T. Hsu (2008)
Cancer Res. 68, 4649-4657
 |  Abstract »  |  Full Text »  |  PDF »

Translation of Genetic Discoveries into Clinical Therapies.

D. G. Hackam and A. S. Hackam (2008)
Ann Intern Med 148, 246-247
 |  Full Text »  |  PDF »

Cancer-Causing Mutations in a Novel Transcription-Dependent Nuclear Export Motif of VHL Abrogate Oxygen-Dependent Degradation of Hypoxia-Inducible Factor.

M. Khacho, K. Mekhail, K. Pilon-Larose, J. Payette, and S. Lee (2008)
Mol. Cell. Biol. 28, 302-314
 |  Abstract »  |  Full Text »  |  PDF »

Imaging Features of von Hippel-Lindau Disease.

R. S. Leung, S. V. Biswas, M. Duncan, and S. Rankin (2008)
RadioGraphics 28, 65-79
 |  Abstract »  |  Full Text »  |  PDF »

Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy.

C. Sourbier, S. Danilin, V. Lindner, J. Steger, S. Rothhut, N. Meyer, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder (2007)
Cancer Res. 67, 11668-11676
 |  Abstract »  |  Full Text »  |  PDF »

Adiposity and Age are Statistically Related to Enhanced RASSF1A Tumor Suppressor Gene Promoter Methylation in Normal Autopsy Kidney Tissue.

I. Peters, B. Vaske, K. Albrecht, M. A. Kuczyk, U. Jonas, and J. Serth (2007)
Cancer Epidemiol. Biomarkers Prev. 16, 2526-2532
 |  Abstract »  |  Full Text »  |  PDF »

Internal En Bloc Resection and Genetic Analysis of Retinal Capillary Hemangioblastoma.

T. Schlesinger, B. Appukuttan, T. Hwang, L.-o. Atchaneeyakasul, C.-C. Chan, Z. Zhuang, J. T. Stout, and D. J. Wilson (2007)
Arch Ophthalmol 125, 1189-1193
 |  Abstract »  |  Full Text »  |  PDF »

Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.

A. Agouni, C. Sourbier, S. Danilin, S. Rothhut, V. Lindner, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder (2007)
Carcinogenesis 28, 1893-1901
 |  Abstract »  |  Full Text »  |  PDF »

Pseudohypoxic Pathways in Renal Cell Carcinoma.

G. Bratslavsky, S. Sudarshan, L. Neckers, and W. M. Linehan (2007)
Clin. Cancer Res. 13, 4667-4671
 |  Abstract »  |  Full Text »  |  PDF »

Mechanisms of Morbid Hearing Loss Associated With Tumors of the Endolymphatic Sac in von Hippel-Lindau Disease.

J. A. Butman, H. J. Kim, M. Baggenstos, J. M. Ammerman, J. Dambrosia, A. Patsalides, N. J. Patronas, E. H. Oldfield, and R. R. Lonser (2007)
JAMA 298, 41-48
 |  Abstract »  |  Full Text »  |  PDF »

Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.

H. Inoue, N. Nonomura, Y. Kojima, M. Shiba, D. Oka, Y. Arai, M. Nakayama, H. Takayama, K. Nishimura, H. Mori, et al. (2007)
Nephrol. Dial. Transplant. 22, 2052-2055
 |  Abstract »  |  Full Text »  |  PDF »

Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease.

D. Angeloni (2007)
Brief Funct Genomic Proteomic
 |  Abstract »  |  Full Text »  |  PDF »

Chromosomes, Hypoxia, Angiogenesis, and Trial Design: A Brief History of Renal Cancer Drug Development.

W. Stadler (2007)
Clin. Cancer Res. 13, 1630-1633
 |  Full Text »  |  PDF »

VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.

E. R. Woodward, K. Wall, J. Forsyth, F. Macdonald, and E. R. Maher (2007)
Brain 130, 836-842
 |  Abstract »  |  Full Text »  |  PDF »

Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomatosis.

W. T. Wong, E. Agron, H. R. Coleman, G. F. Reed, K. Csaky, J. Peterson, G. Glenn, W. M. Linehan, P. Albert, and E. Y. Chew (2007)
Arch Ophthalmol 125, 239-245
 |  Abstract »  |  Full Text »  |  PDF »

Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics.

W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. (2007)
Clin. Cancer Res. 13, 671s-679s
 |  Abstract »  |  Full Text »  |  PDF »

Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma.

M. Yao, Y. Huang, K. Shioi, K. Hattori, T. Murakami, N. Nakaigawa, T. Kishida, Y. Nagashima, and Y. Kubota (2007)
Clin. Cancer Res. 13, 152-160
 |  Abstract »  |  Full Text »  |  PDF »

Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma.

P. H. Patel, R. S.V. Chadalavada, R.S.K. Chaganti, and R. J. Motzer (2006)
Clin. Cancer Res. 12, 7215-7220
 |  Abstract »  |  Full Text »  |  PDF »

Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients.

K.-i. Shioi, A. Komiya, K. Hattori, Y. Huang, F. Sano, T. Murakami, N. Nakaigawa, T. Kishida, Y. Kubota, Y. Nagashima, et al. (2006)
Clin. Cancer Res. 12, 7339-7346
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets.

O. Iliopoulos (2006)
J. Clin. Oncol. 24, 5593-5600
 |  Abstract »  |  Full Text »  |  PDF »

Targeted Therapy for Metastatic Renal Cell Carcinoma.

R. J. Motzer and R. M. Bukowski (2006)
J. Clin. Oncol. 24, 5601-5608
 |  Abstract »  |  Full Text »  |  PDF »

Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma.

K. K. W. To, Z. Zhan, and S. E. Bates (2006)
Mol. Cell. Biol. 26, 8572-8585
 |  Abstract »  |  Full Text »  |  PDF »

The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.

B. Peruzzi, G. Athauda, and D. P. Bottaro (2006)
PNAS 103, 14531-14536
 |  Abstract »  |  Full Text »  |  PDF »

Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?.

C. Jimenez, G. Cote, A. Arnold, and R. F. Gagel (2006)
J. Clin. Endocrinol. Metab. 91, 2851-2858
 |  Abstract »  |  Full Text »  |  PDF »

Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the right hand and hypertension..

O. Iliopoulos, G. Chan-Smutko, R. G. Gonzalez, D. N. Louis, and J. R. Stone (2006)
N. Engl. J. Med. 355, 394-402
 |  Full Text »  |  PDF »

A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage..

B. Pasche (2006)
JAMA 295, 2537-2538
 |  Full Text »  |  PDF »

Von Hippel-Lindau disease and endocrine tumour susceptibility..

E. R Woodward and E. R Maher (2006)
Endocr. Relat. Cancer 13, 415-425
 |  Abstract »  |  Full Text »  |  PDF »

Von Hippel-Lindau Disease: Molecular Pathological Basis, Clinical Criteria, Genetic Testing, Clinical Features of Tumors and Treatment..

T. Shuin, I. Yamasaki, K. Tamura, H. Okuda, M. Furihata, and S. Ashida (2006)
Jpn. J. Clin. Oncol. 36, 337-343
 |  Abstract »  |  Full Text »  |  PDF »

The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy..

C. Sourbier, V. Lindner, H. Lang, A. Agouni, E. Schordan, S. Danilin, S. Rothhut, D. Jacqmin, J.-J. Helwig, and T. Massfelder (2006)
Cancer Res. 66, 5130-5142
 |  Abstract »  |  Full Text »  |  PDF »

Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility.

T. Hsu, Y. Adereth, N. Kose, and V. Dammai (2006)
J. Biol. Chem. 281, 12069-12080
 |  Abstract »  |  Full Text »  |  PDF »

Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma..

N. Nakaigawa, M. Yao, M. Baba, S. Kato, T. Kishida, K. Hattori, Y. Nagashima, and Y. Kubota (2006)
Cancer Res. 66, 3699-3705
 |  Abstract »  |  Full Text »  |  PDF »

Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells.

M. W. Lensch and G. Q. Daley (2006)
Blood 107, 2605-2612
 |  Abstract »  |  Full Text »  |  PDF »

Renal cyst development in mice with conditional inactivation of the von hippel-lindau tumor suppressor..

E. B. Rankin, J. E. Tomaszewski, and V. H. Haase (2006)
Cancer Res. 66, 2576-2583
 |  Abstract »  |  Full Text »  |  PDF »

Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer.

R. E. Banks, P. Tirukonda, C. Taylor, N. Hornigold, D. Astuti, D. Cohen, E. R. Maher, A. J. Stanley, P. Harnden, A. Joyce, et al. (2006)
Cancer Res. 66, 2000-2011
 |  Abstract »  |  Full Text »  |  PDF »

The Tumor Suppressor von Hippel-Lindau Gene Product and Metastasis: New Thoughts on an Old Molecule.

D. Mukhopadhyay (2006)
Am. J. Pathol. 168, 367-369
 |  Full Text »  |  PDF »

Ophthalmic pathology of genotypically confirmed von Hippel Lindau disease type 1.

C M Knapp, G Woodruff, and F Roberts (2006)
Br J Ophthalmol 90, 242-243
 |  Full Text »  |  PDF »

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma.

R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, et al. (2006)
J. Clin. Oncol. 24, 16-24
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.

I. Talon, V. Lindner, C. Sourbier, E. Schordan, S. Rothhut, M. Barthelmebs, H. Lang, J.-J. Helwig, and T. Massfelder (2006)
Carcinogenesis 27, 73-83
 |  Abstract »  |  Full Text »  |  PDF »

Renal-Cell Carcinoma.

H. T. Cohen and F. J. McGovern (2005)
N. Engl. J. Med. 353, 2477-2490
 |  Full Text »  |  PDF »

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib.

J. D. Hainsworth, J. A. Sosman, D. R. Spigel, D. L. Edwards, C. Baughman, and A. Greco (2005)
J. Clin. Oncol. 23, 7889-7896
 |  Abstract »  |  Full Text »  |  PDF »

Jade-1, a candidate renal tumor suppressor that promotes apoptosis.

M. I. Zhou, R. L. Foy, V. C. Chitalia, J. Zhao, M. V. Panchenko, H. Wang, and H. T. Cohen (2005)
PNAS 102, 11035-11040
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma.

M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al. (2005)
Cancer Res. 65, 4598-4606
 |  Abstract »  |  Full Text »  |  PDF »

Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy.

A. Togashi, T. Katagiri, S. Ashida, T. Fujioka, O. Maruyama, Y. Wakumoto, Y. Sakamoto, M. Fujime, Y. Kawachi, T. Shuin, et al. (2005)
Cancer Res. 65, 4817-4826
 |  Abstract »  |  Full Text »  |  PDF »

Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas.

T. W. A. Vogel, F. M. Brouwers, I. A. Lubensky, A. O. Vortmeyer, R. J. Weil, M. M. Walther, E. H. Oldfield, W. M. Linehan, K. Pacak, and Z. Zhuang (2005)
J. Clin. Endocrinol. Metab. 90, 3747-3751
 |  Abstract »  |  Full Text »  |  PDF »

Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers.

A. Agathanggelou, W. N. Cooper, and F. Latif (2005)
Cancer Res. 65, 3497-3508
 |  Abstract »  |  Full Text »  |  PDF »

Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma.

L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, and P.-F. Plouin (2005)
J. Clin. Endocrinol. Metab. 90, 2110-2116
 |  Abstract »  |  Full Text »  |  PDF »

Inactivation of VHL by Tumorigenic Mutations That Disrupt Dynamic Coupling of the pVHL{middle dot}Hypoxia-inducible Transcription Factor-1{alpha} Complex.

F. Miller, A. Kentsis, R. Osman, and Z.-Q. Pan (2005)
J. Biol. Chem. 280, 7985-7996
 |  Abstract »  |  Full Text »  |  PDF »

VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma.

B. I. Rini (2005)
Oncologist 10, 191-197
 |  Abstract »  |  Full Text »  |  PDF »

Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma.

B. I. Rini and E. J. Small (2005)
J. Clin. Oncol. 23, 1028-1043
 |  Abstract »  |  Full Text »  |  PDF »

Coexpression of Erythropoietin and Erythropoietin Receptor in Von Hippel-Lindau Disease-Associated Renal Cysts and Renal Cell Carcinoma.

Y.-S. Lee, A. O. Vortmeyer, I. A. Lubensky, T. W.A. Vogel, B. Ikejiri, S. Ferlicot, G. Benoit, S. Giraud, E. H. Oldfield, W. M. Linehan, et al. (2005)
Clin. Cancer Res. 11, 1059-1064
 |  Abstract »  |  Full Text »  |  PDF »

The von Hippel-Lindau Tumor Suppressor Protein: Roles in Cancer and Oxygen Sensing.

W.G. KAELIN JR. (2005)
Cold Spring Harb Symp Quant Biol 70, 159-166
 |  Abstract »  |  PDF »

The Effect of Von Hippel-Lindau Gene Transfer on Human Vascular Smooth Muscle Cell Proliferation and Apoptosis.

T. Jacob, E. Ascher, A. Hingorani, and S. Kallakuri (2005)
Vascular and Endovascular Surgery 39, 25-32
 |  Abstract »  |  PDF »

Role of VHL Gene Mutation in Human Cancer.

W. Y. Kim and W. G. Kaelin (2004)
J. Clin. Oncol. 22, 4991-5004
 |  Abstract »  |  Full Text »  |  PDF »

The growing family of hereditary renal cell carcinoma.

S. Richard, R. Lidereau, S. Giraud, and on behalf of the French inherited kidney tumours c (2004)
Nephrol. Dial. Transplant. 19, 2954-2958
 |  Full Text »  |  PDF »

Large Germline Deletions of Mitochondrial Complex II Subunits SDHB and SDHD in Hereditary Paraganglioma.

S. R. McWhinney, R. T. Pilarski, S. R. Forrester, M. C. Schneider, M. M. Sarquis, E. P. Dias, and C. Eng (2004)
J. Clin. Endocrinol. Metab. 89, 5694-5699
 |  Abstract »  |  Full Text »  |  PDF »

Vhlh Gene Deletion Induces Hif-1-Mediated Cell Death in Thymocytes.

M. P. Biju, A. K. Neumann, S. J. Bensinger, R. S. Johnson, L. A. Turka, and V. H. Haase (2004)
Mol. Cell. Biol. 24, 9038-9047
 |  Abstract »  |  Full Text »  |  PDF »

Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference.

M. B. Atkins, D. E. Avigan, R. M. Bukowski, R. W. Childs, J. P. Dutcher, T. G. Eisen, R. A. Figlin, J. H. Finke, R. C. Flanigan, D. J. George, et al. (2004)
Clin. Cancer Res. 10, 6277S-6281S
 |  Full Text »  |  PDF »

Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy.

W. M. Linehan, J. Vasselli, R. Srinivasan, M. M. Walther, M. Merino, P. Choyke, C. Vocke, L. Schmidt, J. S. Isaacs, G. Glenn, et al. (2004)
Clin. Cancer Res. 10, 6282S-6289S
 |  Abstract »  |  Full Text »  |  PDF »

The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer.

W. G. Kaelin Jr. (2004)
Clin. Cancer Res. 10, 6290S-6295S
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Markers for Early Detection of Renal Carcinoma: Investigative Approach.

S. Skates and O. Iliopoulos (2004)
Clin. Cancer Res. 10, 6296S-6301S
 |  Abstract »  |  Full Text »  |  PDF »

The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.

R. I. Sufan, M. A. S. Jewett, and M. Ohh (2004)
Am J Physiol Renal Physiol 287, F1-F6
 |  Abstract »  |  Full Text »  |  PDF »

Tumors of the Endolymphatic Sac in von Hippel-Lindau Disease.

R. R. Lonser, H. J. Kim, J. A. Butman, A. O. Vortmeyer, D. I. Choo, and E. H. Oldfield (2004)
N. Engl. J. Med. 350, 2481-2486
 |  Full Text »  |  PDF »

Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development.

D. Pfander, T. Kobayashi, M. C. Knight, E. Zelzer, D. A. Chan, B. R. Olsen, A. J. Giaccia, R. S. Johnson, V. H. Haase, and E. Schipani (2004)
Development 131, 2497-2508
 |  Abstract »  |  Full Text »  |  PDF »

Cancer and Leukemia Group B 90206: A Randomized Phase III Trial of Interferon-{alpha} or Interferon-{alpha} Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma.

B. I. Rini, S. Halabi, J. Taylor, E. J. Small, and R. L. Schilsky (2004)
Clin. Cancer Res. 10, 2584-2586
 |  Abstract »  |  Full Text »  |  PDF »

Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma.

K. Struckmann, P. Schraml, R. Simon, K. Elmenhorst, M. Mirlacher, J. Kononen, and H. Moch (2004)
Cancer Res. 64, 1632-1638
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and Is VHL Mutation Dependent.

M. I. Zhou, H. Wang, R. L. Foy, J. J. Ross, and H. T. Cohen (2004)
Cancer Res. 64, 1278-1286
 |  Abstract »  |  Full Text »  |  PDF »

Developmental Arrest of Angioblastic Lineage Initiates Tumorigenesis in von Hippel-Lindau Disease.

A. O. Vortmeyer, S. Frank, S.-Y. Jeong, K. Yuan, B. Ikejiri, Y.-S. Lee, D. Bhowmick, R. R. Lonser, R. Smith, G. Rodgers, et al. (2003)
Cancer Res. 63, 7051-7055
 |  Abstract »  |  Full Text »  |  PDF »

Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.

N Fernandes da Silva, D Gentle, L B Hesson, D G Morton, F Latif, and E R Maher (2003)
J. Med. Genet. 40, 820-824
 |  Abstract »  |  Full Text »  |  PDF »

Overview: Integrating Renal Hypoxic Signals in Development and Disease.

T. O. Daniel (2003)
J. Am. Soc. Nephrol. 14, 2693-2694
 |  Full Text »  |  PDF »

The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing.

W. G. Kaelin Jr. (2003)
J. Am. Soc. Nephrol. 14, 2703-2711
 |  Abstract »  |  Full Text »  |  PDF »

Influence of the RNA-Binding Protein HuR in pVHL-Regulated p53 Expression in Renal Carcinoma Cells.

S. Galban, J. L. Martindale, K. Mazan-Mamczarz, I. Lopez de Silanes, J. Fan, W. Wang, J. Decker, and M. Gorospe (2003)
Mol. Cell. Biol. 23, 7083-7095
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products